Literature DB >> 1515653

Prognostic significance of the immunohistochemical reaction to human milk fat globule antibodies in node-negative and node-positive breast cancer.

E E Sterns1, W A Fletcher, B Zee.   

Abstract

The status of axillary lymph nodes in patients with breast cancer is important prognostically but does not identify all patients who will have long or short survival. To determine if the immunohistochemical reaction of tumor cells to human milk fat globule (HMFG) antibodies will define prognosis more specifically, we examined patients with node-negative disease and patients with more than three positive nodes, the extremes of the prognostic spectrum. In both node-negative and node-positive groups, patients who relapsed were matched by age at diagnosis, tumor size, histologic type, and receptor status, with patients who remained disease-free for a minimum of 48 months. Patients with poor survival had a higher proportion of poorly differentiated cancers. The ability to generate antigens recognized by HMFG antibodies was decreased in patients with recurrent disease, but this was significant only in patients with node-positive tumors. Tumors of patients who remained disease-free were more likely to have a pattern of membrane staining, while cytoplasmic staining was more frequent in those who relapsed. The results suggest that immunohistologic response to HMFG antibodies may assist in identifying cancers with poor prognosis, supplementing the prediction derived from node status.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1515653     DOI: 10.1007/bf01975002

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  15 in total

1.  Sample size determination in studies with matched pairs.

Authors:  J L Fleiss; B Levin
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

2.  A comparison of three immunoperoxidase techniques for antigen detection in colorectal carcinoma tissues.

Authors:  Z R Shi; S H Itzkowitz; Y S Kim
Journal:  J Histochem Cytochem       Date:  1988-03       Impact factor: 2.479

3.  A new antigen on the epithelial membrane: its immunoperoxidase localisation in normal and neoplastic tissue.

Authors:  E Heyderman; K Steele; M G Ormerod
Journal:  J Clin Pathol       Date:  1979-01       Impact factor: 3.411

4.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

Authors: 
Journal:  N Engl J Med       Date:  1988-12-29       Impact factor: 91.245

5.  Are prognostic factors for local control of breast cancer treated by primary radiotherapy significant for patients treated by mastectomy?

Authors:  P P Rosen; D W Kinne; M Lesser; S Hellman
Journal:  Cancer       Date:  1986-04-01       Impact factor: 6.860

6.  Bilateral cancer of the breast: a review of clinical, histologic, and immunohistologic characteristics.

Authors:  E E Sterns; W A Fletcher
Journal:  Surgery       Date:  1991-10       Impact factor: 3.982

7.  DNA index and S-phase fraction and their combination as prognostic factors in operable ductal breast carcinoma.

Authors:  H Joensuu; S Toikkanen; P J Klemi
Journal:  Cancer       Date:  1990-07-15       Impact factor: 6.860

8.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.

Authors:  C Wright; B Angus; S Nicholson; J R Sainsbury; J Cairns; W J Gullick; P Kelly; A L Harris; C H Horne
Journal:  Cancer Res       Date:  1989-04-15       Impact factor: 12.701

9.  Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failure.

Authors:  E R Fisher; R Sass; B Fisher
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

10.  Patterns of reaction of monoclonal antibodies HMFG-1 and -2 with benign breast tissues and breast carcinomas.

Authors:  J Taylor-Papadimitriou; R Millis; J Burchell; R Nash; L Pang; J Gilbert
Journal:  J Exp Pathol       Date:  1986
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.